Cells of Benign and Borderline Thyroid Tumor Express Malignancy Markers


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅存取

详细

We studied expression of malignancy markers galectin-3, cytokeratin-19, HBME-1, fibronectin, and cyclin D1 in cells of benign (n=51), malignant (n=87), and borderline (n=53) tumors. The results indicate that 3.9% benign and 41.5% borderline tumors express malignancy markers (specificity 98-100%). Follow up over 1-10 years after surgical treatment for borderline tumors showed no progression of tumor growth. We conclude that some benign and borderline tumors represent low-grade neoplasms with favorable prognosis.

作者简介

A. Abrosimov

Endocrinology Research Center, Ministry of Health of the Russian Federation; MISIS National Research Technological University

编辑信件的主要联系方式.
Email: abrosim@mrrc.obninsk.ru
俄罗斯联邦, Moscow; Moscow

N. Dvinskikh

A. F. Tsyb Medical Radiology Center, Affiliated Department of P. A. Hertzen Federal Medical Research Center, Ministry of Health of the Russian Federation

Email: abrosim@mrrc.obninsk.ru
俄罗斯联邦, Obninsk

A. Sidorin

A. F. Tsyb Medical Radiology Center, Affiliated Department of P. A. Hertzen Federal Medical Research Center, Ministry of Health of the Russian Federation

Email: abrosim@mrrc.obninsk.ru
俄罗斯联邦, Obninsk

补充文件

附件文件
动作
1. JATS XML

版权所有 © Springer Science+Business Media New York, 2016